Skip to main content

Table 2 AIC BIC and DIC of OS curve and PFS curve in the Sintilimab group and chemotherapy group (HMC)

From: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China

group

exponential

 

gamma

 

genf

 

gengamma

 

AIC

BIC

DIC

AIC

BIC

DIC

AIC

BIC

DIC

AIC

BIC

DIC

OS curve(sintilimab-combination group)

498.88

506.05

496.86

489.63

500.38

487.39

493.82

511.74

489.17

492.81

507.14

480.77

OS curve(placebo-combination group)

335.27

341.02

333.32

330.15

338.77

328.25

331.91

346.28

327.53

329.40

340.90

327.08

PFS curve(sintilimab-combination group)

825.26

832.42

823.31

809.58

820.33

807.48

813.72

831.63

809.41

809.66

823.99

807.76

PFS curve(placebo-combination group)

515.02

520.77

512.99

491.22

499.85

489.31

494.54

508.92

490.56

491.43

502.93

489.34

group

weibull

 

weibullPH

 

loglogistic

 

lognormal

 

AIC

BIC

DIC

AIC

BIC

DIC

AIC

BIC

DIC

AIC

BIC

DIC

OS curve(sintilimab-combination group)

489.86

500.61

487.96

489.86

500.61

487.76

489.77

500.52

487.92

489.43

500.18

487.35

OS curve(placebo-combination group)

331.00

339.63

329.10

370.16

378.79

751.00

329.83

338.46

327.99

327.90

336.52

325.86

PFS curve(sintilimab-combination group)

810.84

821.59

808.83

810.83

821.58

808.76

809.74

820.49

807.58

807.72

818.47

805.72

PFS curve(placebo-combination group)

493.89

502.52

491.92

493.90

502.52

491.83

490.62

499.25

489.02

489.60

498.23

487.54